Key result
Bovine lactoferricin-lactoferrampin inhibited the replication of Senecavirus A and Foot-and-Mouth Disease Virus and reduced viral loads.
Why the study?
FMDV and SVA are harmful livestock pathogens, and lactoferrin peptides can inhibit viral replication and enhance immune function, prompting investigation into bovine lactoferricin-lactoferrampin effects.
Does bovine lactoferricin-lactoferrampin (LFCA) inhibit the replication of SVA and FMDV and improve cellular antioxidant response in infected models?
Does bovine lactoferricin-lactoferrampin (LFCA) inhibit the replication of SVA and FMDV and improve cellular antioxidant response in infected models?
Answers are grounded in this paper and cite their sources.
LFCA demonstrates potential as an antiviral agent against Senecavirus A and Foot-and-Mouth Disease Virus by inhibiting viral replication and enhancing cellular antioxidant capacity.
Foot-and-mouth disease virus (FMDV) and Senecavirus A (SVA) have similar pathogenic characteristics, and both are important pathogens that harm the livestock industry. Studies have shown that lactoferrin peptides can inhibit the replication of various viruses and enhance the body’s immune functions. Based on this, in the present study, we aimed to investigate the effects of bovine lactoferricin-lactoferrampin (LFCA) on replicating FMDV and SVA and to analyze its role in the cellular antioxidant response caused by viral infection; in addition, we fed mice with constructed recombinant Lactobacillus reuteri expressing LFCA. Treatment with LFCA at different stages significantly inhibited the replication of both SVA and FMDV. Pretreatment before SVA infection achieved an inhibition rate of up to 94.9%, while treatment during the FMDV replication stage achieved an inhibition rate of 74.3%. After infection with either virus, intracellular ROS and MDA levels were significantly reduced, as was GSH-Px activity. However, SOD activity showed no significant difference, compared with the virus-exposed group, and remained at a high level, suggesting an increased cellular antioxidant capacity. LFCA treatment significantly increased the transcription levels of the Nrf2, Ho-1, and Nqo1 genes. In mouse experiments, the LFCA-treated group showed significantly lower viral loads in lung and intestinal tissues, compared with the SVA infection group, validating LFCA’s protective effect against SVA infection. These findings demonstrate the potential of LFCA as an antiviral drug.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied Senecavirus A and Foot-and-Mouth Disease Virus infection. Bovine lactoferricin-lactoferrampin (LFCA) vs. Virus-exposed group was evaluated on Viral replication inhibition. Bovine lactoferricin-lactoferrampin inhibited the replication of Senecavirus A and Foot-and-Mouth Disease Virus and reduced viral loads.
Synapse has enriched 10 related papers. Consider them for comparative context: